Nanoparticulation improves bioavailability of Erlotinib
- Authors
- Yang, Kyung Mi; Shin, In Chul; Park, Joo Won; Kim, Kab-Sig; Kim, Dae Kyong; Park, Kyungmoon; Kim, Kunhong
- Issue Date
- May-2017
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Bioavailability; Erlotinib; fed-fasted variance; NUFS-Ert; pharmacokinetics
- Citation
- DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, v.43, no.9, pp 1557 - 1565
- Pages
- 9
- Journal Title
- DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Volume
- 43
- Number
- 9
- Start Page
- 1557
- End Page
- 1565
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6250
- DOI
- 10.1080/03639045.2017.1326931
- ISSN
- 0363-9045
1520-5762
- Abstract
- Objectives: Nanoparticulation using fat and supercritical fluid (NUFS (TM)) is a drug delivery platform technology enabling efficient and effective formulation of poorly soluble drugs. We performed experiments to examine whether NUFS could improve poor bioavailability and reduce fed-fasted bioavailability variances of erlotinib (Ert). Methods: NUFS-Ert was prepared using NUFS technology; its physical properties were characterized, and drug release was measured. Furthermore, in vitro and in vivo efficacy tests and pharmacokinetic analysis were performed. Results: NUFS-Ert nanoparticles had an average size of 250nm and were stable for 2 months at 40 degrees C, 4 degrees C, and room temperature. The dissolution rate of NUFS-Ert increased in bio-relevant dissolution media. NUFS-Ert was more potent in inhibiting EGF signaling and in suppressing the proliferation of A549, a human non-small cell lung cancer cell line. Furthermore, A549 xenografts in BALB/c nude mice treated with NUFS-Ert regressed more efficiently than those in the mice treated with vehicle or Tarceva (R). In addition, experimental lung metastasis was more efficiently inhibited by NUFS-Ert than by Tarceva (R). The relative bioavailability of NUFS-Ert compared with that of Tarceva (R) was 550% and the ratio of the area under the concentration-time curve (AUC) of fed state to the AUC of fasted state was 1.8 for NUFS-Ert and 5.8 for Tarceva (R). Conclusions: NUFS-Ert could improve poor bioavailability and reduce fed-fasted bioavailability variances of Ert. NUFS-Ert was more efficacious than Tarceva (R).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6250)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.